CANO Insider Transactions
Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
---|---|---|---|---|---|---|---|---|
2024-01-30 | Cooperstone Elliot | 10 percent owner | 526,042 | S-Sale | D | 12,703 | 2.70 | 34,285.00 |
2024-01-31 | Cooperstone Elliot | 10 percent owner | 517,107 | S-Sale | D | 8,935 | 2.59 | 23,177.00 |
2024-02-01 | Cooperstone Elliot | 10 percent owner | 516,007 | S-Sale | D | 1,100 | 2.53 | 2,780.00 |
2024-01-25 | Cooperstone Elliot | 10 percent owner | 612,795 | S-Sale | D | 18,569 | 2.58 | 47,960.00 |
2024-01-26 | Cooperstone Elliot | 10 percent owner | 580,102 | S-Sale | D | 32,693 | 2.74 | 89,736.00 |
2024-01-29 | Cooperstone Elliot | 10 percent owner | 538,745 | S-Sale | D | 41,357 | 2.74 | 113,471.00 |
2024-01-22 | Cooperstone Elliot | 10 percent owner | 740,206 | S-Sale | D | 125,000 | 2.50 | 312,762.00 |
2024-01-23 | Cooperstone Elliot | 10 percent owner | 667,172 | S-Sale | D | 73,034 | 2.94 | 214,800.00 |
2024-01-24 | Cooperstone Elliot | 10 percent owner | 631,364 | S-Sale | D | 35,808 | 2.84 | 101,612.00 |
2024-01-17 | Cooperstone Elliot | 10 percent owner | 971,193 | S-Sale | D | 94,013 | 2.28 | 214,058.00 |
2024-01-17 | Cooperstone Elliot | 10 percent owner | 965,206 | S-Sale | D | 5,987 | 2.92 | 17,489.00 |
2024-01-18 | Cooperstone Elliot | 10 percent owner | 865,206 | S-Sale | D | 100,000 | 1.91 | 191,250.00 |
2024-01-12 | Cooperstone Elliot | 10 percent owner | 1,065,206 | C-Conversion | D | 1,065,206 | 0.00 | 0.00 |
2024-01-12 | Cooperstone Elliot | 10 percent owner | 1,065,206 | C-Conversion | A | 1,065,206 | 0.01 | 10,652.00 |
2024-01-10 | Cooperstone Elliot | 10 percent owner | 49,171 | S-Sale | D | 25,000 | 3.73 | 93,292.00 |
2024-01-11 | Cooperstone Elliot | 10 percent owner | 24,171 | S-Sale | D | 25,000 | 3.59 | 89,790.00 |
2024-01-12 | Cooperstone Elliot | 10 percent owner | 0 | S-Sale | D | 24,171 | 3.30 | 79,878.00 |
2024-01-12 | Cooperstone Elliot | 10 percent owner | 0 | C-Conversion | D | 1,065,206 | 0.00 | 0.00 |
2024-01-05 | Cooperstone Elliot | 10 percent owner | 124,171 | S-Sale | D | 25,000 | 3.85 | 96,232.00 |
2024-01-08 | Cooperstone Elliot | 10 percent owner | 99,171 | S-Sale | D | 25,000 | 3.82 | 95,552.00 |
2024-01-09 | Cooperstone Elliot | 10 percent owner | 74,171 | S-Sale | D | 25,000 | 3.75 | 93,672.00 |
2024-01-02 | Cooperstone Elliot | 10 percent owner | 237,499 | S-Sale | D | 43,505 | 5.42 | 235,658.00 |
2024-01-03 | Cooperstone Elliot | 10 percent owner | 186,681 | S-Sale | D | 50,818 | 4.08 | 207,251.00 |
2024-01-03 | Cooperstone Elliot | 10 percent owner | 162,499 | S-Sale | D | 24,182 | 4.94 | 119,423.00 |
2024-01-04 | Cooperstone Elliot | 10 percent owner | 149,171 | S-Sale | D | 13,328 | 4.00 | 53,297.00 |
2023-12-27 | Cooperstone Elliot | 10 percent owner | 357,313 | S-Sale | D | 37,607 | 5.65 | 212,370.00 |
2023-12-28 | Cooperstone Elliot | 10 percent owner | 316,116 | S-Sale | D | 41,197 | 6.00 | 247,227.00 |
2023-12-29 | Cooperstone Elliot | 10 percent owner | 281,004 | S-Sale | D | 35,112 | 6.00 | 210,644.00 |
2023-12-18 | Flaton Carol | director: | 0 | 0 | 0.00 | 0.00 | ||
2023-12-18 | Ferrari Patricia | director: | 0 | 0 | 0.00 | 0.00 | ||
2023-12-21 | Cooperstone Elliot | 10 percent owner | 449,760 | S-Sale | D | 82,843 | 5.67 | 469,430.00 |
2023-12-21 | Cooperstone Elliot | 10 percent owner | 443,451 | S-Sale | D | 6,309 | 6.62 | 41,765.00 |
2023-12-22 | Cooperstone Elliot | 10 percent owner | 416,074 | S-Sale | D | 27,377 | 5.65 | 154,787.00 |
2023-12-26 | Cooperstone Elliot | 10 percent owner | 394,920 | S-Sale | D | 21,154 | 5.44 | 115,124.00 |
2023-12-15 | Cooperstone Elliot | 10 percent owner | 1,065,206 | C-Conversion | D | 532,603 | 0.00 | 0.00 |
2023-12-15 | Cooperstone Elliot | 10 percent owner | 1,065,206 | C-Conversion | D | 532,603 | 0.00 | 0.00 |
2023-12-15 | Cooperstone Elliot | 10 percent owner | 532,603 | C-Conversion | A | 532,603 | 0.01 | 5,326.00 |
2023-12-07 | TRUJILLO SOLOMON D | director | 136,804 | C-Conversion | A | 136,804 | 0.01 | 1,368.00 |
2023-12-07 | TRUJILLO SOLOMON D | director | 0 | C-Conversion | D | 136,804 | 0.00 | 0.00 |
2023-12-07 | TRUJILLO SOLOMON D | director | 0 | C-Conversion | D | 136,804 | 0.00 | 0.00 |
2023-11-20 | Morales Angel L | director | 69,685 | C-Conversion | A | 69,685 | 0.01 | 696.90 |
2023-11-20 | Morales Angel L | director | 0 | C-Conversion | D | 69,685 | 0.00 | 0.00 |
2023-11-20 | Morales Angel L | director | 0 | C-Conversion | D | 69,685 | 0.00 | 0.00 |
2023-11-10 | Gil Eladio | officer: Interim CFO | 7,676 | A-Award | A | 7,676 | 0.00 | 0.00 |
2023-09-29 | Gil Eladio | officer | 0 | 0 | 0.00 | 0.00 | ||
2023-08-19 | Hernandez Marlow | 0 | 0 | 0.00 | 0.00 | |||
2023-08-11 | Camerlinck Robert | officer: Chief Operating Officer | 26,958,642 | S-Sale | D | 30,646 | 0.77 | 23,453.00 |
2023-07-12 | Kent Mark D. | officer: Interim CEO | 1,529,694 | A-Award | A | 1,138,088 | 0.00 | 0.00 |
2023-07-12 | Kent Mark D. | officer: Interim CEO | 391,606 | A-Award | A | 216,237 | 0.00 | 0.00 |
2023-06-30 | Armstrong David J | officer: See remarks | 664,132 | A-Award | A | 7,506 | 0.77 | 5,780.00 |
2023-07-12 | Hernandez Marlow | director | 4,942,605 | A-Award | A | 189,681 | 0.00 | 0.00 |
2023-06-28 | Aguilar Richard | officer: Chief Clinical Officer | 1,613,984 | S-Sale | D | 150,000 | 1.22 | 183,300.00 |
2023-06-29 | Aguilar Richard | officer: Chief Clinical Officer | 1,213,984 | S-Sale | D | 400,000 | 1.31 | 525,760.00 |
2023-03-31 | Armstrong David J | officer: See remarks | 841,626 | C-Conversion | A | 185,000 | 0.00 | 0.00 |
2023-03-31 | Armstrong David J | officer: See remarks | 689,453 | C-Conversion | D | 185,000 | 0.00 | 0.00 |
2023-03-31 | Armstrong David J | officer: See remarks | 689,453 | C-Conversion | D | 185,000 | 0.00 | 0.00 |
2023-06-26 | Aguilar Richard | officer: Chief Clinical Officer | 4,742,276 | C-Conversion | D | 550,000 | 0.00 | 0.00 |
2023-06-26 | Aguilar Richard | officer: Chief Clinical Officer | 4,742,276 | C-Conversion | D | 550,000 | 0.00 | 0.00 |
2023-06-26 | Aguilar Richard | officer: Chief Clinical Officer | 1,763,984 | C-Conversion | A | 550,000 | 0.00 | 0.00 |
2023-06-16 | Kent Mark D. | officer: Interim CEO | 4,599,564 | I | 0 | 0.00 | 0.00 | |
2023-06-16 | Kent Mark D. | officer: Interim CEO | 2,360,913 | I | 0 | 0.00 | 0.00 | |
2023-06-16 | Kent Mark D. | officer: Interim CEO | 175,369 | D | 0 | 0.00 | 0.00 | |
2023-06-16 | Kent Mark D. | officer: Interim CEO | 174,964 | I | 0 | 0.00 | 0.00 | |
2023-06-15 | TRUJILLO SOLOMON D | director | 378,214 | A-Award | A | 211,581 | 85,000.00 | 17,984,385,000.00 |
2023-06-15 | Rivera Kim M | director | 248,500 | A-Award | A | 185,598 | 50,000.00 | 9,279,900,000.00 |
2023-06-15 | MUNEY ALAN | director | 248,500 | A-Award | A | 185,598 | 50,000.00 | 9,279,900,000.00 |
2023-06-15 | Morales Angel L | director | 248,500 | A-Award | A | 185,598 | 50,000.00 | 9,279,900,000.00 |
2023-06-15 | Guichelaar Jacqueline | director | 248,500 | A-Award | A | 185,598 | 50,000.00 | 9,279,900,000.00 |
2023-05-25 | Aguilar Richard | officer: Chief Clinical Officer | 5,292,276 | C-Conversion | D | 600,000 | 0.00 | 0.00 |
2023-05-25 | Aguilar Richard | officer: Chief Clinical Officer | 5,292,276 | C-Conversion | D | 600,000 | 0.00 | 0.00 |
2023-06-08 | Aguilar Richard | officer: Chief Clinical Officer | 2,089,924 | G-Gift | A | 600,000 | 0.00 | 0.00 |
2023-05-25 | Aguilar Richard | officer: Chief Clinical Officer | 1,889,924 | C-Conversion | A | 675,940 | 0.00 | 0.00 |
2023-06-08 | Aguilar Richard | officer: Chief Clinical Officer | 1,813,984 | S-Sale | D | 275,940 | 1.29 | 356,156.00 |
2023-06-09 | Aguilar Richard | officer: Chief Clinical Officer | 1,713,984 | S-Sale | D | 100,000 | 1.38 | 137,760.00 |
2023-06-07 | Aguilar Richard | officer: Chief Clinical Officer | 1,489,924 | S-Sale | D | 400,000 | 1.32 | 528,400.00 |
2023-06-12 | Aguilar Richard | officer: Chief Clinical Officer | 1,213,984 | S-Sale | D | 500,000 | 1.42 | 711,650.00 |
2023-05-25 | Aguilar Richard | officer: Chief Clinical Officer | 600,000 | C-Conversion | A | 600,000 | 0.00 | 0.00 |
2023-06-08 | Aguilar Richard | officer: Chief Clinical Officer | 0 | G-Gift | D | 600,000 | 0.00 | 0.00 |
2023-05-25 | Aguilar Richard | officer: Chief Clinical Officer | 0 | C-Conversion | D | 675,940 | 0.00 | 0.00 |
2023-05-25 | Aguilar Richard | officer: Chief Clinical Officer | 0 | C-Conversion | D | 675,940 | 0.00 | 0.00 |
2023-06-06 | Armstrong David J | officer: See remarks | 656,626 | S-Sale | D | 3,163 | 1.38 | 4,351.00 |
2023-05-31 | Camerlinck Robert | officer: Chief Operating Officer | 26,989,288 | A-Award | A | 239,139 | 0.00 | 0.00 |
2023-05-31 | Aguilar Richard | officer: Chief Clinical Officer | 1,213,984 | A-Award | A | 231,008 | 0.00 | 0.00 |
2023-05-31 | Koppy Brian D | officer: Chief Financial Officer | 1,050,796 | A-Award | A | 248,226 | 0.00 | 0.00 |
2023-05-31 | Hernandez Marlow | director, officer: CEO | 4,701,256 | A-Award | A | 671,742 | 0.00 | 0.00 |
2023-05-31 | Armstrong David J | officer: See remarks | 659,789 | A-Award | A | 109,526 | 0.00 | 0.00 |
2023-05-31 | Novell Mark | officer: Chief Accounting Officer | 232,067 | A-Award | A | 60,502 | 0.00 | 0.00 |
2023-04-11 | Novell Mark | officer: Chief Accounting Officer | 171,565 | A-Award | A | 51,684 | 0.00 | 0.00 |
2023-04-11 | Novell Mark | officer: Chief Accounting Officer | 32,131 | A-Award | A | 32,131 | 1.50 | 48,196.00 |
2023-04-05 | Camerlinck Robert | officer: Chief Operating Officer | 26,750,149 | J-Other | A | 2,836,540 | 1.50 | 4,254,810.00 |
2023-04-05 | Camerlinck Robert | officer: Chief Operating Officer | 17,163,460 | J-Other | A | 17,163,460 | 0.00 | 0.00 |
2023-04-05 | Camerlinck Robert | officer: Chief Operating Officer | 17,163,460 | J-Other | A | 17,163,460 | 0.00 | 0.00 |
2023-04-05 | Camerlinck Robert | officer: Chief Operating Officer | 0 | S-Sale | D | 20,000,000 | 0.00 | 0.00 |
2023-04-05 | Koppy Brian D | officer: Chief Financial Officer | 802,570 | S-Sale | D | 23,591 | 1.27 | 30,067.00 |
2023-04-05 | Hernandez Marlow | director, officer: CEO | 13,497,686 | S-Sale | D | 8,536,936 | 0.00 | 0.00 |
2023-04-05 | Hernandez Marlow | director, officer: CEO | 13,497,686 | S-Sale | D | 8,536,936 | 0.00 | 0.00 |
2023-04-05 | Hernandez Marlow | director, officer: CEO | 8,536,936 | P-Purchase | A | 8,536,936 | 3.00 | 25,610,808.00 |
2023-04-05 | Aguilar Richard | officer: Chief Clinical Officer | 5,892,276 | S-Sale | D | 4,991,807 | 0.00 | 0.00 |
2023-04-05 | Aguilar Richard | officer: Chief Clinical Officer | 5,892,276 | S-Sale | D | 4,991,807 | 0.00 | 0.00 |
2023-04-05 | Aguilar Richard | officer: Chief Clinical Officer | 4,991,807 | P-Purchase | A | 4,991,807 | 3.00 | 14,975,421.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.